635 related articles for article (PubMed ID: 34062004)
1. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
Richard S; Chari A; Delimpasi S; Simonova M; Spicka I; Pour L; Kriachok I; Dimopoulos MA; Pylypenko H; Auner HW; Leleu X; Usenko G; Hajek R; Benjamin R; Dolai TK; Sinha DK; Venner CP; Garg M; Stevens DA; Quach H; Jagannath S; Moreau P; Levy M; Badros A; Anderson LD; Bahlis NJ; Facon T; Mateos MV; Cavo M; Chang H; Landesman Y; Chai Y; Arazy M; Shah J; Shacham S; Kauffman MG; Grosicki S; Richardson PG
Am J Hematol; 2021 Sep; 96(9):1120-1130. PubMed ID: 34062004
[TBL] [Abstract][Full Text] [Related]
2. Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Mateos MV; Gavriatopoulou M; Facon T; Auner HW; Leleu X; Hájek R; Dimopoulos MA; Delimpasi S; Simonova M; Špička I; Pour L; Kriachok I; Pylypenko H; Doronin V; Usenko G; Benjamin R; Dolai TK; Sinha DK; Venner CP; Garg M; Stevens DA; Quach H; Jagannath S; Moreau P; Levy M; Badros AZ; Anderson LD; Bahlis NJ; Cavo M; Chai Y; Jeha J; Arazy M; Shah J; Shacham S; Kauffman MG; Richardson PG; Grosicki S
J Hematol Oncol; 2021 Apr; 14(1):59. PubMed ID: 33849608
[TBL] [Abstract][Full Text] [Related]
3. Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Auner HW; Gavriatopoulou M; Delimpasi S; Simonova M; Spicka I; Pour L; Dimopoulos MA; Kriachok I; Pylypenko H; Leleu X; Doronin V; Usenko G; Hajek R; Benjamin R; Dolai TK; Sinha DK; Venner CP; Garg M; Stevens DA; Quach H; Jagannath S; Moreau P; Levy M; Badros A; Anderson LD; Bahlis NJ; Facon T; Mateos MV; Cavo M; Chai Y; Arazy M; Shah J; Shacham S; Kauffman MG; Richardson PG; Grosicki S
Am J Hematol; 2021 Jun; 96(6):708-718. PubMed ID: 33755235
[TBL] [Abstract][Full Text] [Related]
4. Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial.
Dolph M; Tremblay G; Leong H
Pharmacoeconomics; 2021 Nov; 39(11):1309-1325. PubMed ID: 34368938
[TBL] [Abstract][Full Text] [Related]
5. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Grosicki S; Simonova M; Spicka I; Pour L; Kriachok I; Gavriatopoulou M; Pylypenko H; Auner HW; Leleu X; Doronin V; Usenko G; Bahlis NJ; Hajek R; Benjamin R; Dolai TK; Sinha DK; Venner CP; Garg M; Gironella M; Jurczyszyn A; Robak P; Galli M; Wallington-Beddoe C; Radinoff A; Salogub G; Stevens DA; Basu S; Liberati AM; Quach H; Goranova-Marinova VS; Bila J; Katodritou E; Oliynyk H; Korenkova S; Kumar J; Jagannath S; Moreau P; Levy M; White D; Gatt ME; Facon T; Mateos MV; Cavo M; Reece D; Anderson LD; Saint-Martin JR; Jeha J; Joshi AA; Chai Y; Li L; Peddagali V; Arazy M; Shah J; Shacham S; Kauffman MG; Dimopoulos MA; Richardson PG; Delimpasi S
Lancet; 2020 Nov; 396(10262):1563-1573. PubMed ID: 33189178
[TBL] [Abstract][Full Text] [Related]
6. Selinexor for the treatment of patients with relapsed or refractory multiple myeloma.
Babar A; Babar M; Zubair H; Shahid A; Rafique S; Bano M; Waleed MS; Khan M; Inayat A; Safi D
J Oncol Pharm Pract; 2024 Apr; 30(3):535-546. PubMed ID: 38454813
[TBL] [Abstract][Full Text] [Related]
7. Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone.
Sanchez L; Leleu X; Beaumont JL; Yu H; Hudgens S; Simonova M; Auner HW; Quach H; Delimpasi S; Špička I; Pour L; Kriachok I; Dimopoulos MA; Usenko G; Hájek R; Benjamin R; Sinha DK; Venner C; Illmer T; Garg MK; Stevens DA; Jagannath S; Levy M; Anderson LD; Bahlis NJ; Facon T; Cavo M; Chai Y; Ma X; Tang S; Leong H; Shah J; Shacham S; Kauffman M; Richardson P; Grosicki S
Am J Hematol; 2021 Oct; 96(10):E383-E386. PubMed ID: 34161627
[No Abstract] [Full Text] [Related]
8. Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma.
Dolph M; Tremblay G; Gilligan AM; Leong H
J Health Econ Outcomes Res; 2021; 8(2):26-35. PubMed ID: 34616855
[No Abstract] [Full Text] [Related]
9. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
Bahlis NJ; Sutherland H; White D; Sebag M; Lentzsch S; Kotb R; Venner CP; Gasparetto C; Del Col A; Neri P; Reece D; Kauffman M; Shacham S; Unger TJ; Jeha J; Saint-Martin JR; Shah J; Chen C
Blood; 2018 Dec; 132(24):2546-2554. PubMed ID: 30352784
[TBL] [Abstract][Full Text] [Related]
10. A Case Report of a 58-Year-Old Woman with a Diagnosis of High-Risk Myeloma Refractory to Multiple Line of Therapy and Treated with Selinexor, Bortezomib, and Dexamethasone Prior to Allogeneic Stem Cell Transplantation.
Cass M; McDonald AB; Ben-Shahar O; Landesman Y; Kashyap T
Am J Case Rep; 2022 Apr; 23():e935353. PubMed ID: 35444159
[TBL] [Abstract][Full Text] [Related]
11. Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk.
Weisel K; Spencer A; Lentzsch S; Avet-Loiseau H; Mark TM; Spicka I; Masszi T; Lauri B; Levin MD; Bosi A; Hungria V; Cavo M; Lee JJ; Nooka A; Quach H; Munder M; Lee C; Barreto W; Corradini P; Min CK; Chanan-Khan AA; Horvath N; Capra M; Beksac M; Ovilla R; Jo JC; Shin HJ; Sonneveld P; Casneuf T; DeAngelis N; Amin H; Ukropec J; Kobos R; Mateos MV
J Hematol Oncol; 2020 Aug; 13(1):115. PubMed ID: 32819447
[TBL] [Abstract][Full Text] [Related]
12. Selinexor-Bortezomib-Dexamethasone: A Review in Previously Treated Multiple Myeloma.
Syed YY
Target Oncol; 2023 Mar; 18(2):303-310. PubMed ID: 36622630
[TBL] [Abstract][Full Text] [Related]
13. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR.
Mateos MV; Sonneveld P; Hungria V; Nooka AK; Estell JA; Barreto W; Corradini P; Min CK; Medvedova E; Weisel K; Chiu C; Schecter JM; Amin H; Qin X; Ukropec J; Kobos R; Spencer A
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):509-518. PubMed ID: 32482541
[TBL] [Abstract][Full Text] [Related]
14. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
Vogl DT; Dingli D; Cornell RF; Huff CA; Jagannath S; Bhutani D; Zonder J; Baz R; Nooka A; Richter J; Cole C; Vij R; Jakubowiak A; Abonour R; Schiller G; Parker TL; Costa LJ; Kaminetzky D; Hoffman JE; Yee AJ; Chari A; Siegel D; Fonseca R; Van Wier S; Ahmann G; Lopez I; Kauffman M; Shacham S; Saint-Martin JR; Picklesimer CD; Choe-Juliak C; Stewart AK
J Clin Oncol; 2018 Mar; 36(9):859-866. PubMed ID: 29381435
[TBL] [Abstract][Full Text] [Related]
15. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
Chari A; Vogl DT; Gavriatopoulou M; Nooka AK; Yee AJ; Huff CA; Moreau P; Dingli D; Cole C; Lonial S; Dimopoulos M; Stewart AK; Richter J; Vij R; Tuchman S; Raab MS; Weisel KC; Delforge M; Cornell RF; Kaminetzky D; Hoffman JE; Costa LJ; Parker TL; Levy M; Schreder M; Meuleman N; Frenzel L; Mohty M; Choquet S; Schiller G; Comenzo RL; Engelhardt M; Illmer T; Vlummens P; Doyen C; Facon T; Karlin L; Perrot A; Podar K; Kauffman MG; Shacham S; Li L; Tang S; Picklesimer C; Saint-Martin JR; Crochiere M; Chang H; Parekh S; Landesman Y; Shah J; Richardson PG; Jagannath S
N Engl J Med; 2019 Aug; 381(8):727-738. PubMed ID: 31433920
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
Patel KK; Parker T; Di M; Bar N; Huntington SF; Giri S
Leuk Lymphoma; 2021 Nov; 62(11):2777-2784. PubMed ID: 34151696
[TBL] [Abstract][Full Text] [Related]
17. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.
Chng WJ; Goldschmidt H; Dimopoulos MA; Moreau P; Joshua D; Palumbo A; Facon T; Ludwig H; Pour L; Niesvizky R; Oriol A; Rosiñol L; Suvorov A; Gaidano G; Pika T; Weisel K; Goranova-Marinova V; Gillenwater HH; Mohamed N; Feng S; Aggarwal S; Hájek R
Leukemia; 2017 Jun; 31(6):1368-1374. PubMed ID: 28025582
[TBL] [Abstract][Full Text] [Related]
18. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study.
Lu J; Fu W; Li W; Hu J; An G; Wang Y; Fu C; Chen L; Jin J; Cen X; Ge Z; Cai Z; Niu T; Qi M; Sun S; Gai X; Liu W; Liu W; Yang X; Huang X
Clin Lymphoma Myeloma Leuk; 2021 Sep; 21(9):e699-e709. PubMed ID: 34108127
[TBL] [Abstract][Full Text] [Related]
19. Selinexor, Bortezomib, and Dexamethasone for Heavily Pretreated Multiple Myeloma: A Case Series.
Magen H; Geva M; Volchik Y; Avigdor A; Nagler A
Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):e947-e955. PubMed ID: 32868229
[No Abstract] [Full Text] [Related]
20. Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma.
Mouhieddine TH; Parekh S; Cho HJ; Richter J; DeCastro A; Shah J; Landesman Y; Chari A; Jagannath S; Madduri D
Ann Hematol; 2021 Dec; 100(12):3057-3060. PubMed ID: 33009581
[No Abstract] [Full Text] [Related]
[Next] [New Search]
